THE USE OF AN ENVIRONMENTAL EXPOSURE CHAMBER (EEC) MODEL FOR CHALLENGING NON-ALLERGIC RHINITIS (NAR) PATIENTS TO IRRITANT TRIGGERS.

被引：0

|

作者：

Lee, J. S.

Wilson, D.

Patel, D.

Bernstein, J. A.

D'Angelo, P.

Salapatek, A.

机构：

来源：

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2009年 / 103卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

引用

收藏

页码：A26 / A26

页数：1

相关论文

共 38 条

[31] Topical treatments based on ectoine, a novel, non-drug, extremophile-based substance, relieves allergic rhinoconjunctivitis symptoms in patients in an environmental exposure chamber model
Bilstein, A.
Salapatek, A.
Patel, P.
Lentzen, G.
ALLERGY, 2011, 66 : 360 - 360
[32] Real-Time Particle Counts Provide a Reliable Indication of Airborne Dust Mite Allergen (Der p 1) Concentration and Ensure Controlled and Safe Exposure for Dust Mite Allergic Patients in an Environmental Exposure Chamber (EEC) Model.
Camuso, N.
Wilson, D.
Lee, J. S.
Salapatek, A.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB20 - AB20
[33] Quality of life (QOL) in ragweed allergic patients treated with Captisol-enabled® eludesonide nasal solution (32μg/spray) when exposed to ragweed pollen in an environmental exposure chamber (EEC) using an EEC-specific rhinoconjunctivitis quality of life questionnaire (EEC-RQOLQ)
Salapatek, A.
McCue, S.
Patel, D.
Patel, P.
Pipkin, J. D.
Zimirer, R. O., Jr.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S55 - S55
[34] Repeated Low-dose Aerosolized Dust Mite Allergen Exposure In Asthmatic And Non-asthmatic Dust Mite Allergic Patients In An Environmental Exposure Chamber Induces Specific Asthma Symptoms As Well As Allergic Rhinoconjunctivitis Symptoms
Patel, D.
Lee, J. S.
Wilson, D.
Camuso, N.
Salapatek, A.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB20 - AB20
[35] The Combination Product Captisol-Enabled® Budesonide plus Azelastine HCI Nasal Spray Provides Significant, Long-lasting Relief of Ocular Allergy Symptoms in Ragweed Allergic Patients Studied in an Environmental Exposure Chamber (EEC)
Patel, P.
Salapatek, A.
D'Angelo, P.
Bates, M.
Patel, D.
Zimmerer, R.
Pipkin, J. D.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S130 - S130
[36] A Phase III Double-Masked, Crossover, Vehicle-Controlled Clinical Trial Conducted in an Environmental Exposure Chamber (EEC) to Study Reproxalap, a Novel, Non-Antihistaminic, Non-Steroidal, Reactive Aldehyde Species Inhibitor for the Treatment for Allergic Conjunctivitis (AC)
Salapatek, Anne Marie
Goyal, Yasmeen
Bundele, Saili
Brady, Todd
Couroux, Peter
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB216 - AB216
[37] Objective measurement of nasal patency with acoustic rhinometry is a superior measure of nasal congestion than subjective symptom scoring and eliminates the placebo effect: Evidence from a clinical trial of mometasone furoate nasal spray in patients with seasonal allergic rhinitis conducted in an environmental exposure chamber
Salapatek, A.
Patel, P.
Gopalan, G.
Varghese, S.
ALLERGY, 2008, 63 : 614 - 614
[38] QUALITY OF LIFE IMPROVED IN RAGWEED ALLERGIC PATIENTS TREATED WITH CAPTISOL-ENABLED® BUDESONIDE plus AZELASTINE NASAL SOLUTION (CDX-313) COMPARED TO PLACEBO AND REFERENCE TREATMENT (AS plus RA) USING AN ENVIRONMENTAL EXPOSURE CHAMBER-SPECIFIC RHINOCONJUNCTIVITIS QUALITY OF LIFE QUESTIONNAIRE (EEC-QOL).
Salapatek, A.
McCuel, S.
Zimmerer, R. O.
Pipkin, J. D.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2009, 103 (05) : A26 - A27

← 1 2 3 4 →